Patrick Baumhof - CureVac NV Senior Technology
| CVAC Stock | USD 2.87 0.13 4.74% |
Executive
Patrick Baumhof is Senior Technology of CureVac NV
| Address | Friedrich-Miescher-Strasse 15, Tübingen, Germany, 72076 |
| Phone | 49 7071 9883 0 |
| Web | https://www.curevac.com |
CureVac NV Management Efficiency
The company has return on total asset (ROA) of (0.2452) % which means that it has lost $0.2452 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.543) %, meaning that it created substantial loss on money invested by shareholders. CureVac NV's management efficiency ratios could be used to measure how well CureVac NV manages its routine affairs as well as how well it operates its assets and liabilities. As of November 29, 2024, Return On Tangible Assets is expected to decline to -0.36. In addition to that, Return On Capital Employed is expected to decline to -0.48. At present, CureVac NV's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 645.8 M, whereas Net Tangible Assets are forecasted to decline to about 407.8 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Rafael Sulit | Anterix | N/A | |
| Gena JD | Anterix | 62 | |
| Kewa Luo | Kandi Technologies Group | 40 | |
| Jason Reid | Stagwell | N/A | |
| Martin Westhead | NETGEAR | 53 | |
| Yanghua Yang | WiMi Hologram Cloud | 35 | |
| Llewellyn Moyer | Deluxe | N/A | |
| Wanjiku JD | 53 | ||
| Kristopher Lazzaretti | Deluxe | N/A | |
| Brian Anderson | Deluxe | N/A | |
| Alice Gonzalez | Anterix | N/A | |
| Timothy CPA | Anterix | 54 | |
| David Kwon | Stagwell | N/A | |
| David Sable | Stagwell | 70 | |
| Bill Watkins | N/A | ||
| Kirsten Daru | NETGEAR | 47 | |
| Malik Ducard | 51 | ||
| Yogaraj Jayaprakasam | Deluxe | 46 | |
| Sabrina Ellis | 51 | ||
| Mike Pienaar | Stagwell | N/A | |
| Doniel Sutton | 50 | ||
Management Performance
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.25 |
CureVac NV Leadership Team
Elected by the shareholders, the CureVac NV's board of directors comprises two types of representatives: CureVac NV inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CureVac. The board's role is to monitor CureVac NV's management team and ensure that shareholders' interests are well served. CureVac NV's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CureVac NV's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Pierre BSc, CFO MD | ||
| Patrick Baumhof, Senior Technology | ||
| AxelSven Malkomes, Chief Officer | ||
| Ronald Plasterk, Senior Innovation | ||
| Igor MSc, Chief Board | ||
| Antony Blanc, Chief MD | ||
| Sarah Fakih, Vice Relations | ||
| LLM LLM, Member CEO | ||
| MD MBA, MD CEO | ||
| Ulrike MD, Senior Oncology | ||
| Slavica StevanovicHeck, Head Resources | ||
| Thorsten Schuller, Head Communications | ||
| Myriam MD, Head Officer | ||
| Malte Greune, Member COO | ||
| Marco LLM, General Counsel |
CureVac Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CureVac NV a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.25 | ||||
| Operating Margin | (4.94) % | ||||
| Current Valuation | 103.82 M | ||||
| Shares Outstanding | 224.34 M | ||||
| Shares Owned By Insiders | 45.26 % | ||||
| Shares Owned By Institutions | 18.86 % | ||||
| Number Of Shares Shorted | 4.41 M | ||||
| Price To Book | 0.85 X | ||||
| Price To Sales | 9.78 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether CureVac NV offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CureVac NV's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Curevac Nv Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Curevac Nv Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CureVac NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade CureVac Stock refer to our How to Trade CureVac Stock guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CureVac NV. If investors know CureVac will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CureVac NV listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.49 | Revenue Per Share 0.294 | Quarterly Revenue Growth 0.905 | Return On Assets (0.25) | Return On Equity (0.54) |
The market value of CureVac NV is measured differently than its book value, which is the value of CureVac that is recorded on the company's balance sheet. Investors also form their own opinion of CureVac NV's value that differs from its market value or its book value, called intrinsic value, which is CureVac NV's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CureVac NV's market value can be influenced by many factors that don't directly affect CureVac NV's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CureVac NV's value and its price as these two are different measures arrived at by different means. Investors typically determine if CureVac NV is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CureVac NV's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.